Optimized factor IX gene
The present invention provides codon optimized Factor IX sequences, vectors and host cells comprising codon optimized Factor IX sequences, polypeptides encoded by codon optimized Factor IX sequences, and methods of producing such polypeptides. The present invention also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor IX nucleic acid sequence or the polypeptide encoded thereby.
1. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO: 1, wherein the nucleotide sequence encodes a factor IX (FIX) polypeptide comprising the amino acid sequence set forth in in SEQ ID NO:3, wherein:
(i) the nucleotide sequence comprises a human codon adaptation index that is increased relative to the sequence set forth in SEQ ID NO:2;
(ii) the nucleotide sequence contains a higher percentage of G/C nucleotides compared to the percentage of G/C nucleotides in the sequence set forth in SEQ ID NO:2;
(iii) the nucleotide sequence does not contain the splice site having the sequence set forth in SEQ ID NO: 4 or 5;
(iv) the nucleotide sequence contains fewer destabilizing elements comprising the sequence set forth in SEQ ID NO: 6 relative to the sequence set forth in SEQ ID NO:2;
(v) the nucleotide sequence contains less repeat sequences relative to the sequence set forth in SEQ ID NO:2;
(vi) the nucleotide sequence contains less antiviral motifs comprising the sequence set forth in SEQ ID NO: 11 relative to the sequence set forth in SEQ ID NO:2;
(vii) the nucleotide sequence does not contain a poly-T sequence;
(viii) the nucleotide sequence does not contain a poly-A sequence comprising a sequence set forth in SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO:8, or any combination thereof; or
(xi) any combination of (i) to (viii).
2. The isolated nucleic acid molecule of claim 1 , wherein:
(i) the human codon adaptation index is at least about 0.75;
(ii) the percentage of G/C nucleotides is at least about 42%;
(iii) the nucleotide sequence contains no destabilizing element;
(iv) the repeat sequences in the isolated nucleic acid molecule include direct repeat, inverted repeat, or dyad repeat sequences;
(v) the nucleotide sequence contains no antiviral motif comprising the sequence set forth in SEQ ID NO: 11; or
(vi) any combination of (i) to (v).
3. The isolated nucleic acid molecule of claim 1 , which further comprises a heterologous nucleotide sequence.
4. The isolated nucleic acid molecule of claim 3 , wherein the heterologous nucleotide sequence encodes a heterologous amino acid sequence that is a half-life extender.
5. The isolated nucleic acid molecule of claim 3 , wherein the heterologous nucleotide sequence encodes a heterologous amino acid sequence, wherein the heterologous amino acid sequence is an immunoglobulin constant region or a portion thereof, transferrin, albumin, XTEN, or a PAS sequence.
6. The isolated nucleic acid molecule of claim 5 , wherein the heterologous amino acid sequence is an Fc region.
7. The isolated nucleic acid molecule of claim 4 , wherein the heterologous amino acid sequence is linked to the N-terminus or the C-terminus of the amino acid sequence encoded by the nucleotide sequence or inserted between two amino acids in the amino acid sequence encoded by the nucleotide sequence.
8. The isolated nucleic acid molecule of claim 3 , which encodes a monomer-dimer hybrid molecule comprising Factor IX.
9. The isolated nucleic acid molecule of claim 1 , operably linked to at least one transcription control sequence.
10. A vector comprising the nucleic acid molecule of claim 1 .
11. A host cell comprising the nucleic acid molecule of claim 1 .
12. The host cell of claim 11 , wherein the host cell is a Chinese hamster ovary (CHO) cell, a human embryonic kidney (HEK) 293 cell, a baby hamster kidney (BHK) 21 cell, a PER.C6 cell, a NS0 cell, or a CAP cell.
13. The isolated nucleic acid molecule of claim 1 , wherein the nucleotide sequence has at least 95% sequence identity to the sequence sete forth in SEQ ID NO: 1.
14. The isolated nucleic acid molecule of claim 1 , wherein the nucleotide sequence comprises the sequence set forth in SEQ ID NO: 1.
15. The isolated nucleic acid molecule of claim 1 , wherein the nucleotide sequence comprises a sequence set forth in SEQ ID NO: 53.
16. The isolated nucleic acid molecule of claim 5 , wherein the heterologous amino acid sequence is an XTEN sequence.
17. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 53, wherein the nucleotide sequence encodes a factor IX (FIX) polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 3.
18. The isolated nucleic acid molecule of claim 17 , wherein the nucleotide sequence has at least 99% sequence identity to the sequence set forth in the SEQ ID NO: 53.
19. The isolated nucleic acid molecule of claim 1 , wherein the nucleotide sequence has at least 99% sequence identity to the sequence set forth in SEQ ID NO: 1.
20. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 90% sequence identity to the sequence set forth in SEQ ID NO: 1, wherein the nucleotide sequence encodes a factor IX (FIX) polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 3.
21. The isolated nucleic acid molecule of claim 20 , wherein the nucleotide sequence has at least 95% sequence identity to the sequence set forth in SEQ ID NO: 1.
22. The isolated nucleic acid molecule of claim 20 , wherein the nucleotide sequence comprises the sequence set forth in SEQ ID NO: 1.